Four U.S. senators introduced a bill aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.
Americans pay the highest prices in the world for cancer drugs, but the treatments are least affordable in lower income countries.
An HIV drug approved less than 3 years ago is to be rolled out in Botswana as a core medicine for newly diagnosed patients.
Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs.
Roche’s breast cancer drug Perjeta (pertuzumab) has been turned down for use on Britain’s state health service.
India has reversed course and granted approval to Gilead Sciences’ patent for its hepatitis C drug Sovaldi.
Regeneron Pharmaceuticals, facing slowing sales of blockbuster eye drug Eylea, said it was making substantial progress in securing more insurance coverage for cholesterol drug Praluent.
France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable.